In May 2021, the FDA granted accelerated approval to amivantamab (Rybrevant) in adult NSCLC patients with locally advanced or metastatic EGFR exon20ins-positive disease following platinum-based chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.